Tjalling Bosse
Impact in
- Obstetrics and Gynecology top 0.02%
- Endometrial and Cervical Cancer Treatments
- Uterine Myomas and Treatments
- Reproductive Medicine top 0.1%
- Ovarian cancer diagnosis and treatment
Papers in
-
- Endometrial and Cervical Cancer Treatments 82
-
- Ovarian cancer diagnosis and treatment 40
- Co-authors
- Carien L. Creutzberg (63 shared papers)Remi A. Nout (46 shared papers)Vincent T.H.B.M. Smit (63 shared papers)David N. Church (22 shared papers)Ellen Stelloo (22 shared papers)Hans W. Nijman (24 shared papers)Jessica N. McAlpine (16 shared papers)Jan J. Jobsen (17 shared papers)
- Journals
- International Journal of Gynecological Cancer (21 papers)Gynecologic Oncology (15 papers)Modern Pathology (11 papers)Clinical Cancer Research (11 papers)International Journal of Gynecological Pathology (9 papers)
- Partner nations
- NetherlandsUnited KingdomCanada
In The Last Decade
Tjalling Bosse
158 papers receiving 9.9k citations
Tjalling Bosse's Hit Papers
Peers
Comparison fields: 5 of 119
- Obstetrics and Gynecology 5.1k
- Reproductive Medicine 2.3k
- Cancer Research 1.5k
- Pathology and Forensic Medicine 1.5k
- Oncology 1.9k
Countries citing papers authored by Tjalling Bosse
This map shows the geographic impact of Tjalling Bosse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tjalling Bosse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tjalling Bosse more than expected).
Fields of papers citing papers by Tjalling Bosse
This network shows the impact of papers produced by Tjalling Bosse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tjalling Bosse. The network helps show where Tjalling Bosse may publish in the future.
Co-authors
The 25 scholars most cited alongside Tjalling Bosse, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 164 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach Hit paper breakdown → | 2019 | 705 |
| 2 | Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts Hit paper breakdown → | 2016 | 590 |
| 3 | ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer Hit paper breakdown → | 2015 | 565 |
| 4 | Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative Hit paper breakdown → | 2015 | 351 |
| 5 | Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2022 | 331 |
| 6 | 2011 | 283 | |
| 7 | Clinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas Hit paper breakdown → | 2019 | 277 |
| 8 | Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer – A pooled analysis of PORTEC 1 and 2 trials Hit paper breakdown → | 2015 | 276 |
| 9 | 2016 | 265 | |
| 10 | Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups Hit paper breakdown → | 2018 | 263 |
| 11 | Interpretation of somatic POLE mutations in endometrial carcinoma Hit paper breakdown → | 2019 | 261 |
| 12 | 2014 | 246 | |
| 13 | 2015 | 236 | |
| 14 | 2016 | 235 | |
| 15 | 2016 | 213 | |
| 16 | 2019 | 209 | |
| 17 | 2019 | 184 | |
| 18 | 2019 | 173 | |
| 19 | 2018 | 168 | |
| 20 | 2013 | 167 |
About Tjalling Bosse
Tjalling Bosse is a scholar working on Obstetrics and Gynecology, Reproductive Medicine, Oncology, Cancer Research and Molecular Biology, having authored 164 papers that have together received 10.0k indexed citations. Recurring topics across this work include Endometrial and Cervical Cancer Treatments (82 papers), Ovarian cancer diagnosis and treatment (40 papers), Genetic factors in colorectal cancer (23 papers), Cancer Genomics and Diagnostics (20 papers), Cervical Cancer and HPV Research (13 papers), BRCA gene mutations in cancer (11 papers), PARP inhibition in cancer therapy (9 papers) and Cancer and Skin Lesions (8 papers). The work is most often cited by research in Obstetrics and Gynecology (5.1k citations), Reproductive Medicine (2.3k citations), Cancer Research (1.5k citations), Pathology and Forensic Medicine (1.5k citations) and Oncology (1.9k citations). Tjalling Bosse has collaborated with scholars based in Netherlands, United Kingdom and Canada. Frequent co-authors include Carien L. Creutzberg, Remi A. Nout, Vincent T.H.B.M. Smit, David N. Church, Ellen Stelloo, Hans W. Nijman, Jessica N. McAlpine, Jan J. Jobsen, Naveena Singh and Alicia León‐Castillo. Their work appears in journals such as International Journal of Gynecological Cancer, Gynecologic Oncology, Modern Pathology, Clinical Cancer Research and International Journal of Gynecological Pathology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.